BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9855331)

  • 1. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.
    Chan JD
    Pharmacotherapy; 1998; 18(6):1304-7. PubMed ID: 9855331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.
    Harnicar S; Adel N; Jurcic J
    J Oncol Pharm Pract; 2009 Sep; 15(3):175-82. PubMed ID: 19282418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma.
    Pana ZD; Roilides E
    Pediatr Blood Cancer; 2011 Jul; 57(1):30-5. PubMed ID: 21265011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing vincristine sulfate medication errors.
    Schulmeister L
    Oncol Nurs Forum; 2004 Sep; 31(5):E90-8. PubMed ID: 15378106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A retrospective analysis of neurotoxicity induced by vinca alkaloids combined with azole anti-fungal agents in hematological malignancies].
    Osato Y; Yokoyama T; Saito Y; Kani R; Hayabe H; Miyamatsu H; Ohyashiki K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1667-72. PubMed ID: 21996963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of vinzolidine.
    Budman DR; Schulman P; Marks M; Vinciguerra V; Weiselberg L; Kreis W; Degnan TJ
    Cancer Treat Rep; 1984; 68(7-8):979-82. PubMed ID: 6744350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
    Saba N; Seal A
    J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine-induced unilateral ptosis in a child.
    Gursel O; Sari E; Altun D; Atay AA; Akin R
    Pediatr Neurol; 2009 Dec; 41(6):461-3. PubMed ID: 19931172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.
    Moriyama B; Henning SA; Leung J; Falade-Nwulia O; Jarosinski P; Penzak SR; Walsh TJ
    Mycoses; 2012 Jul; 55(4):290-7. PubMed ID: 22126626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacology of Catharanthus alkaloids].
    Levêque D; Wihlm J; Jehl F
    Bull Cancer; 1996 Mar; 83(3):176-86. PubMed ID: 8695919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extra- and paravasation of cytotoxic drugs. Pathomechanisms and current preventive measures].
    Lipp HP
    Med Monatsschr Pharm; 2010 Mar; 33(3):87-94; quiz 95-6. PubMed ID: 20355670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plant products in cancer chemotherapy.
    Carter SK; Livingston RB
    Cancer Treat Rep; 1976 Aug; 60(8):1141-56. PubMed ID: 791484
    [No Abstract]   [Full Text] [Related]  

  • 14. Vinca alkaloids.
    Chabner BA; Horwitz SB; Clendennin NJ; Purvis JD
    Cancer Chemother Biol Response Modif; 1991; 12():67-73. PubMed ID: 1681845
    [No Abstract]   [Full Text] [Related]  

  • 15. Bilateral vocal cord paralysis following treatment with vincristine.
    Naithani R; Dolai TK; Kumar R
    Indian Pediatr; 2009 Jan; 46(1):68-9. PubMed ID: 19179723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vincristine: Can its therapeutic index be enhanced?
    Moore A; Pinkerton R
    Pediatr Blood Cancer; 2009 Dec; 53(7):1180-7. PubMed ID: 19588521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of class II beta-tubulin expression by tumor suppressor p53 protein in mouse melanoma cells in response to Vinca alkaloid.
    Arai K; Matsumoto Y; Nagashima Y; Yagasaki K
    Mol Cancer Res; 2006 Apr; 4(4):247-55. PubMed ID: 16603638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe neurotoxicological reaction by combined treatment with vincristine and fluconazole].
    Hellfritzsch M; Lassen P; Nielsen LP
    Ugeskr Laeger; 2013 Apr; 175(15):1042-3. PubMed ID: 23582127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis.
    Sui M; Fan W
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1151-8. PubMed ID: 15752896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.